The purpose of the study is to 1) determine the most practical study recruitment strategies for pregnant and postpartum women with marijuana use and 2) collect data to determine what types of studies pregnant and postpartum women are willing to take part in. Participation involves completing an online survey that takes about 10 minutes to complete.

This study involves partnering with Healthy Start Programs in the SC Pee Dee region to evaluate Listening to Women (LTW), a text message based mental health and substance use screening and referral to treatment program, compared to usual care (Screening, Brief Intervention, and Referral to Treatment (SBIRT)), among pregnant and postpartum women. The study also involves doing interviews and focus groups (group discussions) with women in the Healthy Start programs, community health workers (CHWs), and key local and state stakeholders.

This is a research study to compare a text message based mental health and substance use screening and referral to treatment program, called Listening to Women (LTW), to standard of care mental health and substance use screening. Pregnant and postpartum women ages 18-41 who are receiving prenatal care or who are postpartum are invited to participate.

The main purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in adults with severe postpartum depression (PPD). SAGE-217 is is an investigational drug, which means that it is not yet approved to treat PPD. Participation in the study will last up to 76 days and includes a 14 day treatment period where SAGE-217 is taken by oral pill daily. Visits will take approximately 1 to 3 hours.

This is an open-label study designed to investigate the feasibility and tolerability of a novel TMS treatment protocol to treat depression in women with post-partum depression. It is known that TMS can effectively treat depression. The FDA approved protocol lasts 6 weeks and is not feasible for many women with post-partum depression. We are investigating a 3 day treatment for depression which may be more acceptable for this population. We further hope to characterize the ant-depressant effect of this protocol in order to design a larger trial.